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Abstract
Background: To obtain evidence for the clinical and cost-effectiveness of treatments for patients with rare diseases
is a challenge. Non-dystrophic myotonia (NDM) is a group of inherited, rare muscle diseases characterized by
muscle stiffness. The reimbursement of mexiletine, the expert opinion drug for NDM, has been discontinued in
some countries due to a lack of independent randomized controlled trials (RCTs). It remains unclear however, which
concessions can be accepted towards the level 1 evidence needed for coverage decisions, in rare diseases.
Considering the large number of rare diseases with a lack of treatment evidence, more experience with innovative
trial designs is needed. Both NDM and mexiletine are well suited for an N-of-1 trial design. A Bayesian approach
allows for the combination of N-of-1 trials, which enables the assessment of outcomes on the patient and
group level simultaneously.
Methods/Design: We will combine 30 individual, double-blind, randomized, placebo-controlled N-of-1 trials of
mexiletine (600 mg daily) vs. placebo in genetically confirmed NDM patients using hierarchical Bayesian modeling.
Our results will be compared and combined with the main results of an international cross-over RCT (mexiletine vs.
placebo in NDM) published in 2012 that will be used as an informative prior. Similar criteria of eligibility,
treatment regimen, end-points and measurement instruments are employed as used in the international
cross-over RCT.
Discussion: The treatment of patients with NDM with mexiletine offers a unique opportunity to compare
outcomes and efficiency of novel N-of-1 trial-based designs and conventional approaches in producing
evidence of clinical and cost-effectiveness of treatments for patients with rare diseases.
Trial registration: ClinicalTrials.gov Identifier: NCT02045667
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Background
Rare diseases constitute a heterogeneous group of over
6.000 disorders with a prevalence of <1 per 20.000. In
Europe, 30 million patients (6 to 8% of the population)
have a rare disease [1]. International regulatory authorities
such as the Food and Drug Administration (FDA) and
European Medical Agency (EMA) accept that it is unrea-
sonable to demand the standard level of evidence (level 1)
of multiple Randomized Controlled Trials (RCTs) in
building an evidence-base for treatment of rare diseases
[2-4]. The ability to conduct RCTs in rare diseases is ham-
pered by low numbers of patients and large clinical het-
erogeneity. Relying simply on case reports or case series
incurs a considerable risk of selection and ascertainment
bias. Currently, it is unclear which concessions can be
accepted towards the level 1 evidence needed for coverage
decisions in case of rare diseases [5-7].
The case of mexiletine treatment in Non-dystrophic
myotonia (NDM)
NDM is a heterogeneous group of monogenetic rare dis-
eases caused by mutations in the skeletal muscle chlor-
ide (CLCN1) or the sodium ion channel (SCN4A) genes.
The key symptom is myotonia, a delayed relaxation after
voluntary contraction resulting in muscle stiffness [8].
Apart from muscle stiffness, NDM patients also experi-
ence functionally limiting complaints of pain, fatigue and
weakness [9].
For years, mexiletine (a sodium channel blocker) was
considered the drug of choice for NDMs based on clin-
ical experience. The immediate occasion for our study
was the decision by the National Health Insurance Board
of The Netherlands (and of some other countries), in
2006, to discontinue reimbursement of mexiletine as ra-
tional pharmacotherapy for patients with NDM [10,11].
This decision was based on a Cochrane review that re-
ported the absence of two independent level-1 evidence
studies showing an effect of mexiletine for NDM [12].
Additionally, because of the lack of precise prevalence
numbers of NDM in The Netherlands, the rarity of the
disease was taken into question. As a result, many of
these patients had to discontinue their mexiletine treat-
ment that seemed clinically effective.
In 2012, the Consortium of Clinical Investigation of
Neurological Channelopathies (CINCH) performed an
international multicenter cross-over RCT that showed
the clinical effectiveness of mexiletine as treatment for pa-
tients with NDM over 4 weeks of therapy [13]. Although a
prospective RCT is the gold standard, the effort involved
in conducting such a trial (as well as time, funding and
international cooperation) was substantial, and it will not
always be feasible for rare diseases. New innovative trial
designs may be used to ameliorate problems with small
patient numbers and large clinical heterogeneity.
Combined N-of-1 trials using a Bayesian approach
In an N-of-1 trial, multiple pairs of active treatment and
placebo are offered to an individual patient in a random-
ized, double-blind fashion, while regularly measuring key
endpoints, until efficacy is established or disproved [7].
Due to their design, in which each treatment-pair should
be exchangeable in time, N-of-1 trials are especially suit-
able for the investigation of treatments in chronic, symp-
tomatic conditions, where period effects (i.e. changes
in disease state) and carry over effects (i.e. lingering drug
effect) are small. This is the case for a number of neuro-
logical, reumatological, psychiatric and pulmonary disor-
ders [14]. N-of-1 trials are hardly applicable to surgical,
quickly progressive or acute medical conditions [15]. The
method has been originally developed to identify the best
treatment option for an individual patient in case of genu-
ine doubt concerning treatment benefit by formalization
of what a physician does on a daily basis [14,16].
Major advantages of N-of-1 trials from the point of
view of the patient and the treating physician are: (1) an
N-of-1 trial determines whether the treatment is actually
of benefit in the individual patient as opposed to some per-
centage of a group of patients; (2) the N-of-1 trial avoids
the possibly unethical “therapeutic misconception” of the
RCT - where most subjects are convinced they are receiv-
ing effective treatment even though told there is a 50/50
chance they will receive placebo (and that the treatment
may not be effective) [16-19].
More recently, data from multiple N-of-1 trials have
been combined (or meta-analyzed) to produce estimates
of treatment effect at a population level (i.e. combined
N-of-1 trials) [20-22]. For this purpose, Bayesian hier-
archical models have been developed [23,24]. Bayesian
models use a different approach, which does not rely on
the hypothesis testing/confidence intervals paradigm of
traditional (frequentist) statistical methods, but allows de-
termination of the posterior probability of whether a treat-
ment effect is beneficial. Additionally, Bayesian methods
allow for the use of prior available information (e.g. previ-
ous trial results) within the analysis [7].
Hypothesis
The key hypothesis is that combining data from multiple
N-of-1 trials using Bayesian statistics is a promising ap-
proach to produce evidence of clinical and cost-effectiveness
of treatments for patients with rare diseases. As a case
study we will investigate mexiletine in NDM. Results of
this approach will be compared with the results of a
conventional RCT approach.
Study objectives:
(I). To use Bayesian methods for combining N-of-1
trials to obtain evidence of the clinical and
cost-effectiveness of mexiletine in the treatment
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of NDM, on patient and population level
simultaneously.
(II). To compare this approach with a conventional
RCT approach.
Both NDM and mexiletine are well suited for an N-of-1
trial design: NDM is a stable disease; mexiletine acts rap-
idly and its effect quickly subsides upon discontinuation
of treatment; effects can be readily and objectively mea-
sured; and patients are eager to cooperate.
The Bayesian approach taken in this study will allow
for considering questions on patient level and a popula-
tion level simultaneously and it offers additional flexibility
for customizing the trial length for individual patients.
Furthermore, there is relevant clinical prior information
(data from the previously conducted RCT) that can be in-
corporated into Bayesian analysis together with our new
trial data.
Methods/Design
Design
In this study a series of double-blind, randomized and
placebo-controlled N-of-1- trials is conducted. Each in-
dividual N-of-1 trial consists of one to four treatment sets,
each comprising 11 weeks. A treatment set comprises two
treatment periods: a four-week period of active treatment
(mexiletine) and a four-week period of treatment with
placebo, with a one-week wash-out in between treat-
ment periods and two weeks for statistical analysis
(individual interim analysis) at the end of each treat-
ment set. Within each treatment set, the order in
which mexiletine and placebo will be offered will be
randomized (block-randomization). Total study duration
will be between 11 and 44 weeks per patient, depending on
the amount of treatment sets needed to produce convin-
cing evidence of clinical effectiveness or ineffectiveness of
mexiletine (Figure 1). Results of the individual N-of-1 trials
will be combined to produce estimates of population clin-
ical and cost-effectiveness by using a hierarchical Bayesian
model [25]. The trial is performed at the Radboud University
Medical Center in Nijmegen, The Netherlands.
Study population
Based on a sample size calculation (see below), thirty
NDM patients will be included. Eligible patients have a
genetically confirmed diagnosis of NDM, carry one (or
two, in case of autosomal recessive inheritance) causative
mutation(s) in the skeletal muscle chloride (CLCN1) or
sodium (SCN4A) channel gene, and are at least 18 years of
age and live in The Netherlands, Belgium or Germany.
A previous study in the Dutch NDM population showed
a diagnostic yield of 100% for in tandem analysis of these
two genes [26]. Inclusion and exclusion criteria, including
co-medication are presented in Table 1.
Recruitment and screening
Our center of expertise has developed a nation-wide
registry of patients with NDM. As described previously,
for this registry we asked all Dutch neurologists and the
Dutch Patient Association for Neuromuscular Diseases
(Spierziekten Nederland), to notify us of patients with
NDM. Patients (>18 years) were invited to our neurology
outpatient clinic in Nijmegen, The Netherlands, for clin-
ical assessment, needle-EMG, and collection of blood
Figure 1 Study design individual N-of-1 trials.
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samples for genetic analysis [8,12,26-29]. In 2007, the
registry contained 62 NDM patients with a genetically
confirmed NMD. Between 2007 and 2014, 48 genetically
confirmed patients have been added, resulting in a total of
110 registered patients with extensive phenotypic and
genotypic characterization. Asymptomatic carriers are not
represented in the registry.
Potentially eligible patients will be selected from the
registry. We expect that a maximum of 40% may not be
eligible to participate, because of cardiac conditions, kid-
ney or hepatic failure or neurological diseases other than
NDM. Out of the remaining patients, random stratified
samples will be taken, of 15 patients with a chloride chan-
nelopathy (TMC or BMC) and 15 patients with a sodium
channelopathy (PMC or SCM). During a screening visit
information about the study will be given, and patients
will be asked to provide written informed consent. Eligibil-
ity will be checked by taking medical history and by con-
ducting venous blood test (blood urea nitrogen, serum
chloride, carbon dioxide, creatinine, blood glucose, serum
potassium, serum sodium), ECG, and urine pregnancy
testing for females. Serum pregnancy testing can be per-
formed if, in the opinion of the investigator, the urine
pregnancy test is inconclusive. Dosage, duration and date
of last use of phenytoin, carbamazepine or mexiletine will
be documented.
We will document characteristics of ineligible or ex-
cluded patients to estimate the external validity of our
findings. Participants who are taking antiarrhythmics or
medication that may affect sodium channels, will have a
wash-out period before the baseline visit (Table 1, point 7).
For the duration of the study, patients are instructed to
comply with the study medication regime as supplied in
the treatment kits.
Intervention
Treatment conditions:
(1) Mexiletine hydrochloride 200 mg capsules, three
times daily per os (PO)
(2) Placebo capsules, three times daily PO
Randomisation and preparation of study drugs
A statistician will generate computer-based randomization
schemes, and will send these to the hospital pharmacy
that is in charge of the distribution of medication. Mexile-
tine will be purchased from Agenzia Industrie Difesa -
Stabilimento Chemico Farmaceutico Militare in Florence
(Italy) where mexiletine is produced under Good Medicinal
Practice (GMP) conditions. Mexiletine will be released by a
Qualified Person.
Treatment kits will be prepared by the department of
Pharmacy of our hospital. Following computer-generated
randomization drug packaging and labelling will take
place at our department of Pharmacy. At the start of the
first set (see below) patients will receive a blinded,
randomly-ordered treatment kit that contains medication
for the entire set. In each set, patients will receive 4-week
treatment with mexiletine, 200 mg 1 times a day PO (first
week, day 1), 200 mg 2 times a day PO (first week, day 2)
and 200 mg 3 times a day PO (remaining days of first
week and second, third and fourth week), placebo will be
provided in a similar build-up scheme with placebo tablets
PO. The placebo is microcrystalline cellulose (supplied
by Spruyt Hillen). The mexiletine and placebo are standard
orange colored capsules (size nr. 00). We will count capsules
to determine compliance at the end of the study. In case
of study discontinuation, reasons will be documented.
Outcomes and measurements
Primary outcome measure
Interactive voice response diary (IVR) The primary
endpoint will be the severity score of stiffness reported
via the IVR. The primary endpoint is the same as in the
RCT by Statland et al. [13]. The IVR is an automated
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. At least 18 years of age 1. Inability or willingness to approved to provide informed consent
2. Genetically confirmed
diagnosis of NDMs
2. Other neurological conditions that might affect the assessment of the study measurement
3. Genetically confirmed DM1 (CTG > repeats), or DM2
4. Existing cardiac conduction defects, evidenced on ECG including but not limited to the following condition:
malignant arrhythmia or cardiac conduction disturbance (such as second degree AV block, third degree AV block,
or prolonged QT interval >500 ms or QRS duration > 150 msec)
5. Current use of the following antiarrhythmic medication for a cardiac disorder: flecainide acetate, encainide,
disopyramide, procainamide, quinidine, propafenone or mexiletine
6. Women who are pregnant or lactating
7. Currently on medication for myotonia such as phenytoin and flecainide acetate within 5 days of enrollment,
carbamazepine and mexiletine within 3 days of enrollment, or propafenone, procainamide, disopyramide,
quinidine and encainide within 2 days of enrollment
8. Renal or hepatic disease, heart failure, history of myocardial infarction, or seizure disorders
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centralized, real-time response phone-system that records
severity and frequency of symptoms (stiffness, pain, weak-
ness, and tiredness) and has been validated in patients
with myotonia [30]. Patients will call in on a daily basis
during the last two weeks of each four-weeks treatment
period to rate (1) if they experienced symptoms during
the past 24 hours and (2) the severity of the symptoms on
an ordinal scale (1 to 9; 1 being minimal and 9 the worst
ever experienced) using their telephone key pad. The IVR
has been translated for this study [30].
Secondary outcome measures
Severity scores of pain, weakness, and tiredness will be
documented as measured by the IVR from daily calls
made by participants during the last two weeks of each
four-weeks treatment period.
Questionnaires
1. The Individual Neuromuscular Quality of Life
questionnaire (INQoL) has been validated in skeletal
muscle channelopathies such as NDM [31]. The
questionnaire consists of 45 questions within 10
sections, four sections focus on the impact of
muscle disease symptoms, five sections focus on the
impact of muscle disease on particular areas of life,
and one section focuses on the positive and negative
effects of treatment. A composite score can be
derived representing overall QOL. No Dutch version
was available. With granted authorization from the
authors, a translation into Dutch language has been
used in patients with a chronic neuromuscular
disease [32].
2. The Short-Form 36-Item Health Status Survey (SF-36,
Dutch version) is a generic questionnaire to
establish the self-reported health status of patients.
The questionnaire consists of the following domains:
physical functioning (10 items), role functioning
physical (four items), social functioning (two
items), body pain (two items), mental health (five
items), vitality (four items), general-health perception
(five items), and change in health [33]. In addition
summary composite scores for mental and physical
functioning are derived. SF-36 domain scores from a
Dutch nationwide sample of healthy individuals have
been published [34].
Standardized interview All interviews will be conducted
by the same investigator (BCS). During the screening visit,
answers to four open, standardized questions will be noted
and recorded on video: 1. What is the most invalidating
symptom or daily life disability that would make you take
anti-myotonic medication? 2. Do you expect mexiletine to
have a positive effect on your myotonic symptoms? 3.
What kind of improvement would you need to experience
for you to continue mexiletine treatment after the trial? 4.
How important is a positive treatment-effect for you?
Apart from the standardized interview, co-morbidity,
previous and current use of medication (also anti-myotonic
treatment) will be reported. After each treatment set, the
patients’ preference for one of the two treatment periods
within the treatment-set, will be noted.
Clinical myotonia bedside tests
1. Eyelid closure action myotonia is defined as an
increased muscle relaxation time of the orbicularis
oculi and smaller upper and lower eyelid muscles
(often between 1 – 15 sec) after forceful eyelid
closure. The participant will be instructed to close
the eyes as forcefully as possible for five seconds
then rapidly open their eyes on command. This will
be repeated five times in sequence. For each
attempt, the time from the command to open their
eyes until relaxation of the eyelid closure muscles
will be timed and noted up to two decimals.
2. Hand-grip action myotonia is defined as an
increased muscle relaxation time of the finger flexor
muscles and some of the involved underarm flexor
muscles (often between 1 – 15 sec) after a forceful
handgrip. The participant will be instructed to
forcefully close the fingers of the right hand in a fist
(handgrip) for five seconds, while resting the back of
the right hand on a table, and then, on command,
rapidly open the fist on command. This will be
repeated five times in sequence. For each attempt,
the time from the command to open the right fist
until relaxation of the handgrip muscles to the point
that the fingertips of dig II-V reach the surface of the
table will be timed and noted up to two decimals.
Both eyelid-closure action myotonia and handgrip
action myotonia have been previously used to redefine
clinical phenotypes [8] or as therapeutic outcome
measure [13].
3. The Timed Up&Go (TUG) measures the time in
which the participant rises from a chair, walks three
meters, turns around, walks back and sits down
again in a self-selected speed. The TUG has shown
intra- and inter-reliability and has been validated in
patients with non-dystrophic myotonia [35,36].
4. Quantitative Grip Myotonia: Maximum Voluntary
Isometric Contractions (MVICs) of the long finger
flexors and the subsequent relaxation time
(myotonia) will be measured using a technique
developed at the University of Rochester [37]. To
measure the extent of grip myotonia of resting
forearm muscle, each participant will squeeze the
grip handle with a maximum grip for three seconds
then relax until the force returns to baseline. The
relaxation time from 90% to 5% of maximal force
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following this initial MVIC will be used to calculate
the degree of myotonia. Each participant will
perform three sets of five MVICs. Each set will be
separated by a 10-minute rest period. Additionally,
for each MVIC, we will analyze the peak force (PF)
and the decline (%) of this PF within the three seconds
duration of the MVIC (as a measure for the
phenomenon of transient paresis).
All clinical myotonia bedside tests will be conducted
by the same examiner (BCS).
Measurement of myotonic discharges with needle-
EMG Concentric needle EMG will be performed in
the left rectus femoris muscle at rest. This muscle was
chosen based on our previous studies on NDM [8,38]. Ac-
cording to established criteria of Streib et al. [39] myo-
tonic discharges will be defined and quantified during 10
insertions, each followed by 30 sec of visual and auditory
identification of myotonic discharges. Myotonic dis-
charges must be at least 500 milliseconds, with potential
amplitudes ranging from 10 μV to 1 mV, waxing and wan-
ing in both amplitude and frequency. Grading of myotonic
discharges: 0: No positive muscle activity or an occasional
run of positive waves following needle movement (detec-
tion of myotonia in 0-2/10 insertions); 1+: Myotonia ful-
filling the minimal requirements (detection of myotonic
discharges in 3-5/10 insertions) 2+: myotonic discharges
in more than one-half of needle insertions (detection of
myotonic discharges in 6-9/10 insertions); 3+: myotonic
discharges with each needle movement in all examined
areas (detection of myotonic discharges in 10/10 inser-
tions) [39]. The EMG signals will be amplified and filtered
between 20 Hz and 3 kHz and stored using the liveplay
feature of the Medelec Synergy EMG equipment (software
version 10; Oxford Instruments Medical, UK) to facilitate
future quantification of myotonic discharge characteristics
[38]. All needle-EMG investigations will be performed by
or under supervision of an experienced clinical neuro-
physiologist (CGS).
Mexiletine-serum concentration
Serum samples for random drug levels determination
will be obtained during the visits at the start and end of
every treatment period. All serum samples will be ana-
lyzed at once, at the end of the trial, by our department
of Pharmacology and Toxicology. Analysis will be based
upon a previously published protocol using liquid chro-
matography [40].
Cost-effectiveness
Health care consumption will be assessed by using a
modified version of the Client Service Receipt Inventory
(CSRI), which will be filled in by the patients at the end
of each treatment period [41,42]. The CSRI measures
direct neuromuscular disease-related health care costs
(including costs of visits to other health care providers:
GPs, specialist care, physical therapy, psychological ther-
apy, social worker contacts), professional home care and
hospitalization, as well as non-health care costs such as
costs for paid and unpaid help. Additional prescribed
and over the counter medication will also be recorded.
For unit cost prices, standard rates will be adopted from
the national guideline [43] or real cost prices (e.g., for
medication) will be obtained through the website of
the Dutch Health Care Insurance Boards (Zorginstituut
Nederland, http://www.medicijnkosten.nl). The price year
will be 2014 and the currency Euros. Costs per patient will
be calculated by multiplying resource volumes by unit
costs. Costs and effects (in terms of QoL) will be com-
bined to assess cost-effectiveness. If mexiletine appears to
be more effective and more expensive –or less effective
and less expensive- than placebo, the cost-effectiveness will
be expressed in terms of the incremental cost-effectiveness
ratio (ICER). Nonparametric bootstrapping techniques
will be used to produce confidence intervals around mean
costs, mean effectiveness and (if necessary) the ICER.
General structure of the study
Initial screening will be scheduled 2 weeks prior to the
baseline visit. During study enrolment patients will have
4-16 outpatient clinic visits depending on number of treat-
ment sets necessary to obtain enough evidence (Figure 1).
Each visit will take approximately 1-1.5 hours and com-
prises two questionnaires, clinical myotonia bedside tests,
ECG and venous blood collection for measurement of
mexiletine blood serum levels. Needle-EMG investigations
will be performed at the end of each treatment period
(Table 2).
Patients who exhibit convincing evidence of a genuine
positive effect will be offered to continue to use mexile-
tine (see section: statistical analysis – individual interim
analyses). After completion of the individual N-of-1 trials,
patients will be followed up for three months, to monitor
clinical progression, drug compliance, adverse events and
quality of life.
Safety
ECGs taken at the beginning and end of each treatment
period will be screened for abnormalities (conduction
times: PR, QRS and QTc-time; and the presence of car-
diac arrhythmia by an experienced cardiologist). Cardiac
arrhythmias will be classified as clinically relevant or irrele-
vant. Clinically relevant arrhythmia and conduction disor-
ders will be presented to the Data and Safety Monitoring
Board (DSMB).
During the study, patients are instructed to directly re-
port serious adverse events, non-serious adverse events
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(such as gastro-intestinal discomfort or nausea) are
reported during trial visits.
Quality assurance/monitoring
The Clinical Trial Center of the Radboud University
Medical Center Nijmegen, Nijmegen (“Clinical Research
Center Nijmegen” (CRCN); www.crcn.nl) will be respon-
sible for the data quality management and monitoring of
this trial.
Ethical approval and registration
This study has been reviewed and approved by the med-
ical ethics committee of the region Arnhem-Nijmegen,
The Netherlands, (reference CMO nr. NL34801.091.10)
and has been registered at clinicaltrials.gov (ClinicalTrials.
gov Identifier: NCT02045667). Patients receive verbal and
written information about the study and written informed
consent will be obtained before randomization.
Data safety monitoring board
There will be bi-annual controls by the data safety moni-
toring board, which consist of a clinical pharmacologist,
a cardiologist and a biostatistician. This committee will
analyze all severe adverse events, drop-outs due to adverse
medical events and mortalities.
Statistical analysis
Sample size and power
The IVR measure for stiffness (a 9-points scale) is our
primary endpoint. No minimal clinically important dif-
ference (MCID) calculation for the IVR was available
from the literature. We chose an MCID of 0.75 on the
mean IVR-score as clinically relevant difference based on
clinical expert opinion and a previously reported within
subject standard deviation (SD) of 1.5 (with ½ SD as a
distribution-based estimate for the MCID [44]) [30]. The
mean IVR score in the published RCT was 4.21 (95%
confidence interval 3.40 - 5.20) on placebo [13]).
The data of the combined N-of-1 trials will be
analyzed using a hierarchical Bayesian model [45]. Since
no formula-based methodology exists for sample size or
power calculations for such designs, we have performed
a simulation-based sample size calculation.
The simulation-based sample size calculation consisted
of the following steps: (1) Drawing a random realization
from a prior distribution for the mean treatment effect,
based on expert opinion. (2) For each of these realizations,
we have simulated data for 30 N-of-1 trials using R soft-
ware, where the data for each N-of-1 trial consisted of 2 ×
10 × 2 observations (for 2 treatment arms, 10 observations
per arm per treatment pair, and 2 completed treatment
pairs). These simulations were performed using a model
structure with a random intercept and a random slope for
Table 2 Schedule of study measurements during the screenings phase and the first treatment set
Mexiletine or placebo (period 1) Wash-out and
cross- over
Mexiletine or placebo (period 2) Interim
analysis 1
Actions Screening Week 1,
day 1
Week 2,
day 1
Week 3,
day 1
Week 4,
day 7
Week 5 Week 6,
day 1
Week 7,
day 1
Week 8,
day 1
Week 9,
day 7
Week
10
Week
11
Lab test X
Pregnancy test X
Consent X
Medical history X
ECG X X X
Needle EMG X X
IVR X X X* X* X X X* X*
INQoL/SF-36 X X X X
Clinical myotonia
tests
X X X X
Quantative grip
myotonia
X X X X
Mexiletine blood
plasma levels
X X X X
Dispense drug/
placebo
X
Collect medication
bottles
X X
Study measurements for a possible second, third and fourth treatment set are identical to the measurements in the first treatment set and are not represented in
this table.
X* = daily collection of IVR data.
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different individuals and a residual within-person error.
(3) Each simulated data set of 30 N-of-1 trials was analyzed
as described by Zucker et al. [22]. We have combined each
of the simulated data sets with a normally distributed prior
distribution with a mean of 1.75 and a standard deviation
of 0.89, which was also based on expert opinion. (4) Each
of these Bayesian analyses resulted in a marginal posterior
distribution for the mean treatment effect β0. (5) For each
of these posterior distributions we determined the poster-
ior probability of a treatment effect of at least 0.75. We
assumed that all participants will be subjected to two
treatment pairs. Steps 1 - 5 were re-iterated 1000 times,
resulting in 1000 posterior probabilities of a clinically
meaningful treatment effect. From these 1000 probabilities
we have determined the mean, which corresponds to an
estimate of the expected posterior probability of a sub-
stantial treatment effect. The mean expected posterior
probability of a clinically meaningful treatment effect was
0.82. Thus, under the specified assumptions, with the
results of 30 patients with NDM completing the trial, we
would be 82% certain that mexiletine produces a clinically
meaningful treatment effect in these patients.
Prior elicitation, informative and non-informative priors
The strength of Bayesian analyses is that it provides an
algorithm for updating the probability estimate of a par-
ticular claim being true (e.g., the claim that mexiletine
produces, on average, an improvement of at least 0.75
on the IVR stiffness scale in patients with NDM, when
compared to placebo) whenever novel relevant evidence
becomes available. The information that was already
available before the novel evidence became available is
expressed as prior distributions (so called “priors”). For
all model parameters a prior will be needed, however,
since the mean treatment difference is the parameter of
main interest, these priors will receive the most atten-
tion. In the main analysis an informative prior based
on data on the treatment effect from the previous study
(i.e. treatment effect in the RCT by Statland et al. [13]) will
be used. In a sensitivity analysis we will use a prior for the
treatment effect based on expert opinion, in which case
they are elicited from expert physicians: expert neuromus-
cular neurologists with experience in the pharmacological
treatment of NDM patients. These neurologists will be
asked to estimate the treatment effect based on patient
demographic information, genetic information and video-
clips of the baseline myotonia bedside tests. A histogram-
based method (Spiegelhalter ([46], p.145) will be used to
elicit individual (i.e. from each neurologist) clinical priors,
which will subsequently be aggregated to provide one
group clinical prior. Another sensitivity-analysis will be
performed with a non-informative prior for the group
level mean treatment effect instead of the informative
priors. For all other model parameters we will use non-
informative (or ‘flat’) priors, since it is difficult to
elicit parameters such as random effect variations from
physicians [46].
Individual interim analyses
After treatment sets 1, 2 and 3 of each N-of-1 trial we
will investigate whether the existing evidence at that mo-
ment is sufficient to conclude that one of the two treat-
ments is more effective for that particular individual.
This will be done by a statistician who is blinded for
treatment allocation and who will use Bayesian methods.
The patient and the treating physician will be advised to
discontinue the N-of-1 trial if the posterior probability
of a treatment effect larger than 0.75 (clinically relevant
mean difference) is at least 80% (discontinue trial par-
ticipation and start regular treatment) or at most 20%
(discontinue trial participation and do not start regular
treatment). In all other cases they will be advised to con-
tinue the N-of-1 trial. Taking into account this advice,
the physician and patient will discuss the effects of treat-
ment, as observed by the physician and experienced by
the patient, and together they will decide whether or not
to continue the N-of-1 trial.
For our interim analysis we will use non-informative
priors only, as we prefer to base our stopping advice on
the patient data.
Bayesian hierarchical analysis
This study aims to answer the following questions: What
is the probability that mexiletine is clinically effective in
patients with non-dystrophic myotonia (NDM) on the in-
dividual and group level? To combine the results of the
multiple N-of-1 trials, a hierarchical (multi-level) Bayesian
model will be used, with the IVR measure for stiffness as
the dependent variable, and with the patient and the sub-
group (chloride versus sodium channel mutation carriers)
as the structural grouping factors (or the levels of the
model). The patient will be treated as a random effect
(both a random intercept and a random slope), while
subgroup of patients and mutation type will be treated as
fixed effects. The within person residual variance will
similarly be assumed to be drawn from a common distri-
bution. In the main analysis, the prior will be based on the
RCT results from Statland et al [13]. Sensitivity analyses
with a clinical prior and with a non-informative prior will
also be performed. From the Bayesian analysis we will ob-
tain posterior distributions for the mean treatment effect
at the population level, as well as posterior distributions
for the treatment effects at the individual level, that will
exhibit borrowed strength from the population estimates
through shrinkage to the population mean. For details of
the procedure to be used, see Zucker et al. [22].
Also, we will investigate interactions between treatment
effect and treatment set, and between treatment effect
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and treatment order. Secondary endpoints will be
analyzed similarly.
Comparisons with the RCT and traditional analysis methods
In addition to synthesizing the data from our study with
the existing RCT evidence, we will also contrast the out-
comes of the two studies. To this end, a sensitivity ana-
lysis with a non-informative prior will be performed.
This will provide a direct comparison of the outcomes of
the two studies. In order to compare the novel method-
ology of combined N-of-1 trials with more traditional
analysis methods, we will perform a (non-Bayesian) fre-
quentist analysis of our data, where the same approach
will be chosen as in the previous cross-over RCT by
Statland et al. [13].
Discussion
In conclusion, our study offers a unique opportunity to
assess the validity and feasibility of Bayesian analyses of
combined N-of-1 trial methodology to obtain evidence of
the clinical and cost-effectiveness of drugs for rare diseases,
at the individual and group level simultaneously.
Furthermore, our approach, if valid and feasible, may
reduce costs compared to an international RCT, and
enables clinicians to potentially run trials in the setting
of out-patient clinic visits.
As such, our study may serve as a model for future re-
search into treatments in other rare genetic diseases, and
will help to bridge the gap between research and clinical
practice.
Apart from this methodological objective, results of
our study will contribute to the current level of evidence
of the clinical-effectiveness of mexiletine in NDM and
may clarify the cost-effectiveness of mexiletine treatment
in NDM patients.
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